Results 221 to 230 of about 22,015 (248)

Biosimilars

2017
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma, Raj K. Keservani, Rajesh K. Kesharwani   +2 more
openaire   +2 more sources

Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity

Eye, 2022
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D. Kuppermann   +4 more
openaire   +3 more sources

Biosimilars

rheuma plus, 2014
H. Grabowski, G. Long, R. Mortimer
  +6 more sources

Biosimilar Basics

Journal of Infusion Nursing, 2020
openaire   +2 more sources

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Lancet Oncology, The, 2021
Zhenggang Ren, Qiu Li, Yajin Chen
exaly  

Biosimilars – Biosimilars: ja, aber

Aktuelle Rheumatologie, 2015
openaire   +1 more source

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Lancet, The, 2017
Espen A Haavardsholm, Knut E A Lundin, Jørgen Jahnsen   +2 more
exaly  

Biosimilars

International Journal of Pharmaceutical Medicine, 2007
Schellekens, H., Jiskoot, W., Crommelin, D.J.A.   +2 more
openaire   +3 more sources

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
Beyong Duk Ye, Adi Lahat, Sigal Fishman
exaly  

Infliximab biosimilar CT-P13 in Crohn's disease

Lancet, The, 2019
Geert D'Haens
exaly